Disclosures for "E326K GBA Polymorphism is Associated with Clinical and Pathological Features of Synucleinopathy in the Absence of Overt Parkinson’s Disease or Lewy Body Dementia"
-
Ms. Arnold has received intellectual property interests from a discovery or technology relating to health care.
-
Randall L. Woltjer has nothing to disclose.
-
Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Retrophin. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Disease Cooperative Study. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Therapeutic Research Institute. Dr. Quinn has a non-compensated relationship as a consultant with Cognition Therapeutics that is relevant to AAN interests or activities.